PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS
Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | LARSON, Ryan P YEE, Nathan K SUTHERLAND, Claire L DEVRIES, Todd RAMSBORG, Christopher Glen HAUSE, Ronald James Jr DAVE, Kedar Himanshu YOST, Rachel K |
| description | Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.
L'invention concerne des procédés, des compositions et des articles manufacturés destinés à être utilisés en thérapie cellulaire impliquant l'administration d'une ou de plusieurs doses d'une composition de lymphocytes T thérapeutiques, ainsi que des procédés, des compositions et des articles manufacturés destinés à être utilisés dans celle-ci. Les cellules de la composition de lymphocytes T expriment des récepteurs recombinés tels que des récepteurs chimériques, p. ex. des récepteurs antigéniques chimériques (CAR) ou d'autres récepteurs transgéniques, tels que les récepteurs des lymphocytes T (TCR). Les caractéristiques des modes de réalisation de la présente invention, parmi lesquelles figurent la dose de cellules ou d'unités de cellules administrés et/ou le phénotype des cellules administrées, procurent divers avantages, tels qu'un dosage stable, un risque de toxicité moins élevé et/ou une réponse accrue chez les sujets recevant lesdites compositions de lymphocytes T. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2019113559A9</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2019113559A9</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2019113559A93</originalsourceid><addsrcrecordid>eNrjZDAP8HD18w-JDPB0VvB1DPJ2DQpWcPMPUnB29fFRCPFwDXIMiFRw9HNRCHL1cQxxdVHwdQ3x8HcJ5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgaGloaGxqamlo6WxsSpAgDdVikq</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS</title><source>esp@cenet</source><creator>LARSON, Ryan P ; YEE, Nathan K ; SUTHERLAND, Claire L ; DEVRIES, Todd ; RAMSBORG, Christopher Glen ; HAUSE, Ronald James Jr ; DAVE, Kedar Himanshu ; YOST, Rachel K</creator><creatorcontrib>LARSON, Ryan P ; YEE, Nathan K ; SUTHERLAND, Claire L ; DEVRIES, Todd ; RAMSBORG, Christopher Glen ; HAUSE, Ronald James Jr ; DAVE, Kedar Himanshu ; YOST, Rachel K</creatorcontrib><description>Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.
L'invention concerne des procédés, des compositions et des articles manufacturés destinés à être utilisés en thérapie cellulaire impliquant l'administration d'une ou de plusieurs doses d'une composition de lymphocytes T thérapeutiques, ainsi que des procédés, des compositions et des articles manufacturés destinés à être utilisés dans celle-ci. Les cellules de la composition de lymphocytes T expriment des récepteurs recombinés tels que des récepteurs chimériques, p. ex. des récepteurs antigéniques chimériques (CAR) ou d'autres récepteurs transgéniques, tels que les récepteurs des lymphocytes T (TCR). Les caractéristiques des modes de réalisation de la présente invention, parmi lesquelles figurent la dose de cellules ou d'unités de cellules administrés et/ou le phénotype des cellules administrées, procurent divers avantages, tels qu'un dosage stable, un risque de toxicité moins élevé et/ou une réponse accrue chez les sujets recevant lesdites compositions de lymphocytes T.</description><language>eng ; fre</language><subject>BEER ; BIOCHEMISTRY ; CHEMISTRY ; COMPOSITIONS THEREOF ; CULTURE MEDIA ; ENZYMOLOGY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; MICROBIOLOGY ; MICROORGANISMS OR ENZYMES ; MUTATION OR GENETIC ENGINEERING ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS ; SPIRITS ; VINEGAR ; WINE</subject><creationdate>2020</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200625&DB=EPODOC&CC=WO&NR=2019113559A9$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20200625&DB=EPODOC&CC=WO&NR=2019113559A9$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LARSON, Ryan P</creatorcontrib><creatorcontrib>YEE, Nathan K</creatorcontrib><creatorcontrib>SUTHERLAND, Claire L</creatorcontrib><creatorcontrib>DEVRIES, Todd</creatorcontrib><creatorcontrib>RAMSBORG, Christopher Glen</creatorcontrib><creatorcontrib>HAUSE, Ronald James Jr</creatorcontrib><creatorcontrib>DAVE, Kedar Himanshu</creatorcontrib><creatorcontrib>YOST, Rachel K</creatorcontrib><title>PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS</title><description>Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.
L'invention concerne des procédés, des compositions et des articles manufacturés destinés à être utilisés en thérapie cellulaire impliquant l'administration d'une ou de plusieurs doses d'une composition de lymphocytes T thérapeutiques, ainsi que des procédés, des compositions et des articles manufacturés destinés à être utilisés dans celle-ci. Les cellules de la composition de lymphocytes T expriment des récepteurs recombinés tels que des récepteurs chimériques, p. ex. des récepteurs antigéniques chimériques (CAR) ou d'autres récepteurs transgéniques, tels que les récepteurs des lymphocytes T (TCR). Les caractéristiques des modes de réalisation de la présente invention, parmi lesquelles figurent la dose de cellules ou d'unités de cellules administrés et/ou le phénotype des cellules administrées, procurent divers avantages, tels qu'un dosage stable, un risque de toxicité moins élevé et/ou une réponse accrue chez les sujets recevant lesdites compositions de lymphocytes T.</description><subject>BEER</subject><subject>BIOCHEMISTRY</subject><subject>CHEMISTRY</subject><subject>COMPOSITIONS THEREOF</subject><subject>CULTURE MEDIA</subject><subject>ENZYMOLOGY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>MICROBIOLOGY</subject><subject>MICROORGANISMS OR ENZYMES</subject><subject>MUTATION OR GENETIC ENGINEERING</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</subject><subject>SPIRITS</subject><subject>VINEGAR</subject><subject>WINE</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2020</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDAP8HD18w-JDPB0VvB1DPJ2DQpWcPMPUnB29fFRCPFwDXIMiFRw9HNRCHL1cQxxdVHwdQ3x8HcJ5mFgTUvMKU7lhdLcDMpuriHOHrqpBfnxqcUFicmpeakl8eH-RgaGloaGxqamlo6WxsSpAgDdVikq</recordid><startdate>20200625</startdate><enddate>20200625</enddate><creator>LARSON, Ryan P</creator><creator>YEE, Nathan K</creator><creator>SUTHERLAND, Claire L</creator><creator>DEVRIES, Todd</creator><creator>RAMSBORG, Christopher Glen</creator><creator>HAUSE, Ronald James Jr</creator><creator>DAVE, Kedar Himanshu</creator><creator>YOST, Rachel K</creator><scope>EVB</scope></search><sort><creationdate>20200625</creationdate><title>PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS</title><author>LARSON, Ryan P ; YEE, Nathan K ; SUTHERLAND, Claire L ; DEVRIES, Todd ; RAMSBORG, Christopher Glen ; HAUSE, Ronald James Jr ; DAVE, Kedar Himanshu ; YOST, Rachel K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2019113559A93</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2020</creationdate><topic>BEER</topic><topic>BIOCHEMISTRY</topic><topic>CHEMISTRY</topic><topic>COMPOSITIONS THEREOF</topic><topic>CULTURE MEDIA</topic><topic>ENZYMOLOGY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>MICROBIOLOGY</topic><topic>MICROORGANISMS OR ENZYMES</topic><topic>MUTATION OR GENETIC ENGINEERING</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS</topic><topic>SPIRITS</topic><topic>VINEGAR</topic><topic>WINE</topic><toplevel>online_resources</toplevel><creatorcontrib>LARSON, Ryan P</creatorcontrib><creatorcontrib>YEE, Nathan K</creatorcontrib><creatorcontrib>SUTHERLAND, Claire L</creatorcontrib><creatorcontrib>DEVRIES, Todd</creatorcontrib><creatorcontrib>RAMSBORG, Christopher Glen</creatorcontrib><creatorcontrib>HAUSE, Ronald James Jr</creatorcontrib><creatorcontrib>DAVE, Kedar Himanshu</creatorcontrib><creatorcontrib>YOST, Rachel K</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LARSON, Ryan P</au><au>YEE, Nathan K</au><au>SUTHERLAND, Claire L</au><au>DEVRIES, Todd</au><au>RAMSBORG, Christopher Glen</au><au>HAUSE, Ronald James Jr</au><au>DAVE, Kedar Himanshu</au><au>YOST, Rachel K</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS</title><date>2020-06-25</date><risdate>2020</risdate><abstract>Provided are methods, compositions and articles of manufacture for use in cell therapy involving the administration of one or more doses of a therapeutic T cell composition, and methods, compositions and articles of manufacture for use in the same. The cells of the T cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). Features of the embodiments of the present disclosure, including the dose of cells or units of cells administered and/or the phenotype of administered cells, provide various advantages, such as consistent dosing, lower risk of toxicity and/or increased response in subjects administered the T cell compositions.
L'invention concerne des procédés, des compositions et des articles manufacturés destinés à être utilisés en thérapie cellulaire impliquant l'administration d'une ou de plusieurs doses d'une composition de lymphocytes T thérapeutiques, ainsi que des procédés, des compositions et des articles manufacturés destinés à être utilisés dans celle-ci. Les cellules de la composition de lymphocytes T expriment des récepteurs recombinés tels que des récepteurs chimériques, p. ex. des récepteurs antigéniques chimériques (CAR) ou d'autres récepteurs transgéniques, tels que les récepteurs des lymphocytes T (TCR). Les caractéristiques des modes de réalisation de la présente invention, parmi lesquelles figurent la dose de cellules ou d'unités de cellules administrés et/ou le phénotype des cellules administrées, procurent divers avantages, tels qu'un dosage stable, un risque de toxicité moins élevé et/ou une réponse accrue chez les sujets recevant lesdites compositions de lymphocytes T.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2019113559A9 |
| source | esp@cenet |
| subjects | BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPIRITS VINEGAR WINE |
| title | PHENOTYPIC MARKERS FOR CELL THERAPY AND RELATED METHODS |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T04%3A37%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LARSON,%20Ryan%20P&rft.date=2020-06-25&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2019113559A9%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |